AstraZeneca announced that its PROVENT Phase-III prophylaxis trial of its antibody cocktail therapy AZD7442 met the primary goal of preventing COVID-19 in late-stage cases. Read all you need to know.
from Jagran Josh https://ift.tt/3k73dgs
from Jagran Josh https://ift.tt/3k73dgs
No comments:
Post a Comment